Dermatological vs. gyn. MDTM
|
0.95
|
0.01 to 93.97
|
.981
| | | |
Gastrointestinal vs. gyn. MDTM
|
288.58
|
0.28 to >999.00
|
.109
|
7.36
|
1.38 to 39.35
|
.020**
|
Head and neck cancer vs. gyn. MDTM
|
1.94
|
0.17 to 22.07
|
.593
| | | |
Liver and biliary tract vs. gyn. MDTM
|
1.99
|
0.20 to 19.57
|
.552
| | | |
Lymphoma and myeloma vs. gyn. MDTM
|
4.85
|
0.17 to 135.52
|
.351
| | | |
Neuro-oncological vs. gyn. MDTM
|
2.81
|
0.12 to 68.75
|
.524
|
5.39
|
1.24 to 23.45
|
.025**
|
Non-entity-specific oncological vs. gyn. MDTM
|
5.45
|
0.08 to 386.63
|
.433
| | | |
Non-entity-specific surgical vs. gyn. MDTM
|
14.44
|
0.29 to 730.38
|
.181
| | | |
Thorax vs. gyn. MDTM
|
1.28
|
0.00 to >999.00
|
.944
| | | |
Uro-oncological vs. gyn. MDTM
|
21.27
|
0.31 to >999.00
|
.154
| | | |
Number of attending professionals (1 person increase)
|
0.90
|
0.71 to 1.13
|
.352
| | | |
Duration of session (10 min increase)
|
0.82
|
0.36 to 1.84
|
.630
| | | |
Number of cases discussed in this session (1 case increase)
|
1.20
|
0.82 to 1.76
|
.347
| | | |
Quality of case historya
|
0.64
|
0.02 to 26.76
|
.813
| | | |
Quality of radiological informationa
|
0.74
|
0.39 to 1.41
|
.359
| | | |
Quality of information on comorbiditiesa
|
1.12
|
0.79 to 1.59
|
.532
| | | |
Presentation of whether case was palliative (dichotomous variable)
|
0.52
|
0.11 to 2.42
|
.399
| | | |
Quality of psychosocial informationa
|
0.95
|
0.57 to 1.60
|
.836
| | | |
Quality of information on the patient’s views and preferencesa
|
1.10
|
0.72 to 1.69
|
.661
| | | |
Number of active participants in the discussion of each individual case (1 person increase)
|
0.89
|
0.60 to 1.33
|
.571
| | | |
Quality of chair behaviora
|
1.24
|
0.68 to 2.26
|
.704
| | | |
Quality of team behaviora
|
1.32
|
0.58 to 3.01
|
.508
| | | |
Medical and treatment uncertainty during case discussiona
|
2.12
|
1.39 to 3.23
|
.001**
|
2.16
|
1.48 to 3.14
|
<.001**
|
Duration of case discussion (1 min increase)
|
1.13
|
0.94 to 1.43
|
.203
| | | |